Error message

Enter key-codes to unlock Personalized Downloads field is required.

"Thanks to new Multiplicom test kits physicians are able to identify all the genetic mutations of a condition at once, and use this information to initiate the right - personalized - treatment.”

Our DNA

We believe that molecular diagnostic kits are essential to providing everyone with access to effective, affordable and personalized medicine.

read more

OUR WHY

By detecting a genetic predisposition to certain illnesses at an early stage we make personalized medicine possible. That allows us to contribute to improved quality of life and to a healthier society.

OUR HOW

We take the information that is stored in the DNA of each individual to provide correct and reliable information about the origin of certain illnesses, or to better understand a potential predisposition to these illnesses. That allows the physician to intervene more quickly and efficiently through personalized medicine. Early diagnosis and targeted treatment results in improved health of the individual without increasing the healthcare costs for society! This way we opt for an affordable and accessible approach.

OUR WHAT

We develop simple, efficient and reliable molecular diagnostic test kits to collect genetic information for personalized treatment.

close


Our Values

Everything starts with our continuous search for INNOVATIVE test kits in molecular diagnostics. Our objective is to translate complexity into practical solutions. Using our expertise, we aim to provide clinical laboratories user-friendly applications. Quickly and correctly. TRUSTWORTHY for all stakeholders.

read more

There is only an added value to collecting genetic information early if the individual BENEFITS from it. Early prevention or the appropriate medical approach. Because everyone should be entitled to personalized medicine. APPROACHABLE for all. We therefore continue to invest in various domains: human genetics, onco genetics and prenatal genetics.

We do this with an open mind and a healthy INTERNATIONAL ambition. Because we believe that personalized medicine must not only open frontiers, it must cross those frontiers as well.

close


Our History

Founded in 2011 as a spin-off from the University of Antwerp and VIB, Multiplicom achieved end of 2012 its first CE-IVD-certification for the BRCA MASTR Dx assay for breast and ovarian cancer predisposition. It was the first company in Europe achieving a BRCA CE-IVD certification and it continues to develop and market quality controlled MPS-based assays. Therefore, it enables clinical laboratories to diagnose patients with a genetic disease or predisposition, steer cancer therapy, and identify congenital defects early in pregnancy. On January 20, 2017, Agilent Technologies acquired Multiplicom N.V. With the completion of the acquisition, the Multiplicom team is a part of the Genomics Division within Agilent’s Diagnostics & Genomics Group. 

read more

close


Quality Standards

Our MASTR technology has been developed and proven to obtain a high level of reliability. We aim to register our major products under the CE-IVD directives and maintain an ISO13485 quality standard.

read more

CE-IVD

 

CE marked Products

Multiplicom has heavily invested in setting up a quality system that meets the European CE-IVD requirements.  As a result, the company has been able to design, develop and manufacture CE-IVD products that are conform to the Essential requirements outlined in Annex I of the IVD Directive. Multiplicom's CE-IVD products that are placed on the market are therefore safe, effective and suitable for their purpose.

  • BRCA MASTR Dx (2012) for Breast and Ovarian Cancer
  • CFTR MASTR Dx (2014) for Cystic Fibrosis
  • FMF MASTR Dx (2014) for Familial Mediterranean Fever
  • Clarigo (2015) screens for the aneuploidy status of chromosomes 21, 18 and 13 early in pregnancy
  • BRCA Tumor MASTR Plus Dx (2016) for the identification of mutations in BRCA1 and BRCA2 in FFPE tumor samples
  • SOMATIC 1 MASTR Plus Dx (2016) for the identification of mutations in NRAS, KRAS and BRAF genes in cancer patients

 

 

Benefits of Multiplicom's Dx, CE-IVD products

  • Offers greater confidence on results obtained
  • Guarantees that reagents have been designed and manufactured in such way that do not compromise, directly or indirectly, the clinical condition or the safety of the patients and the safety or health of those utilizing the kit during the testing
  • Facilitates the accreditation process of a medical laboratory performing clinical testing services while reducing evaluation costs

Download CE-IVD BRCA MASTR Dx - CFTR MASTR Dx - FMF MASTR Dx - 454 MID Dx - MID Dx Illumina MiSeq

 

ISO Certification

ISO CertificationMultiplicom has obtained recognized Quality Management System certification ISO 13485:2003 & EN ISO 13485:2012 for the design, development, manufacture and distribution of in-vitro molecular diagnostic products used for identification of genomic and somatic variants. ISO 13485 is a harmonized international standard that specifies the requirements for the company's quality management system. Certification bodies use this standard to assess the company's ability to meet customer and regulatory requirements. The ISO 13485 certification establishes Multiplicom as a reliable supplier of diagnostic kits to clinical labs, as well as, to the major diagnostic companies worldwide. 

close


Management Team

Dirk Pollet

Dirk Pollet


Chief Executive Officer

Dirk Pollet

Prior to joining Multiplicom upon successful conclusion of its Series A financing on April 15th 2011, Dirk Pollet was Chief Business Officer at Cellectis since November 2008 as executive consultant for Dircs bvba. Before starting his own consultancy business Dircs bvba, he was Senior Vice President Licensing & IP at Galapagos NV in Belgium and member of the Executive Team. Prior to joining Galapagos NV in 2000, Dr. Pollet was Director Molecular Diagnostics at Glaxo Welcome in Stevenage UK. Before that he started and built the diagnostics group at Innogenetics NV where he stayed for fourteen years. Dirk Pollet holds a PhD in Biochemistry from the University of Antwerp.

Jurgen Del Favero

Jurgen Del Favero


Chief Technology Officer

Prof. Dr. Jurgen Del Favero

Prof. Dr. Jurgen Del Favero is the scientific founder of Multiplicom and acting Chief Technology Officer since the founding of the company. He is also professor at the University of Antwerp where he is leading the VIB Applied Molecular Genomics unit. Next to his scientific research in the field of psychiatric genetics, his work focuses on the development and implementation of novel nucleic acid based technologies and bioinformatics tools. He is the inventor of the technology that gave rise to Multiplicom.

Luc Segers

Luc Segers


Vice-President Marketing & Sales

Luc Segers

Luc Segers has over 25 years of experience in the clinical diagnostics industry in international commercialization, business development and strategic planning. Previously he was Senior Director Business Development at MDxHealth (formerly OncoMethylome Sciences) active in the oncology field. Prior to MDxHealth, he served as global Director Sales & Marketing at Innogenetics’ diagnostics division, and before that in several marketing positions at Organon Teknika. Mr. Segers holds a masters degree in Industrial Biochemistry.

Vicky Gwosdz

Vicky Gwosdz


Chief Financial Officer

Vicky Gwosdz

Vicky Gwosdz was Finance Manager at GTSC (J&J) between 2009 and 2011. Between 2006 and 2009 she was active as freelance author of multiple finance books and taught finance techniques at VU Amsterdam. As Head of Finance at Galapagos between 2004 and 2006, she played an important role in the company’s IPO.

Paul Vauterin

Paul Vauterin


Vice-President Informatics

Dr. Paul Vauterin

Dr. Paul Vauterin coordinates the software development activities at Multiplicom. Prior to joining Multiplicom, he worked at the University of Oxford where he was the chief architect of a suite of web-based innovative analysis and visualization tools for large-scale population genetics data. Before that, he co-founded the company Applied Maths and developed the BioNumerics software platform, which has become a global standard for the analysis of bacterial molecular typing data. Paul Vauterin holds a PhD in theoretical physics from the University of Ghent.

Ina Vandenbroucke


Vice-President Operations

Dr. Ina Vandenbroucke 

Prior to joining Multiplicom, Ina Vandenbroucke worked at Biocartis, where she gained extensive experience in IVD development in the field of oncology and infectious diseases. She held various R&D management positions and headed the Assay Design and Development team. Before joining Biocartis in 2010, Ina worked at Tibotec-Virco, Janssen Diagnostics for 7 years, where she was responsible for development of diagnostic assays in the field of virology. She implemented Next Generation Sequencing in the company, and successfully developed several NGS assays with her team. Ina holds a PhD in Medical Sciences from Ghent University.

Career Opportunities